Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Debt (2016 - 2020)

Historic Non-Current Debt for Amicus Therapeutics (FOLD) over the last 11 years, with Q2 2020 value amounting to $147.8 million.

  • Amicus Therapeutics' Non-Current Debt rose 57.15% to $147.8 million in Q2 2020 from the same period last year, while for Jun 2020 it was $147.8 million, marking a year-over-year increase of 57.15%. This contributed to the annual value of $147.4 million for FY2019, which is 43.62% up from last year.
  • As of Q2 2020, Amicus Therapeutics' Non-Current Debt stood at $147.8 million, which was up 57.15% from $147.6 million recorded in Q1 2020.
  • Over the past 5 years, Amicus Therapeutics' Non-Current Debt peaked at $147.8 million during Q2 2020, and registered a low of $38.5 million during Q1 2016.
  • For the 4-year period, Amicus Therapeutics' Non-Current Debt averaged around $118.5 million, with its median value being $146.8 million (2019).
  • In the last 5 years, Amicus Therapeutics' Non-Current Debt soared by 31821.24% in 2016 and then surged by 36.97% in 2019.
  • Amicus Therapeutics' Non-Current Debt (Quarter) stood at $44.0 million in 2016, then skyrocketed by 233.13% to $146.7 million in 2018, then rose by 0.44% to $147.4 million in 2019, then rose by 0.31% to $147.8 million in 2020.
  • Its Non-Current Debt was $147.8 million in Q2 2020, compared to $147.6 million in Q1 2020 and $147.4 million in Q4 2019.